Skip to main content Accessibility help
×
Home

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

  • Jeffrey W. Swanson (a1), Marvin S. Swartz (a1), Richard A. Van Dorn (a2), Jan Volavka (a3), John Monahan (a4), T. Scott Stroup (a5), Joseph P. McEvoy (a1), H. Ryan Wagner (a1), Eric B. Elbogen (a1) and Jeffrey A. Lieberman (a6)...

Abstract

Background

Violence is an uncommon but significant problem associated with schizophrenia

Aims

To compare antipsychotic medications in reducing violence among patients with schizophrenia over 6 months, identify prospective predictors of violence and examine the impact of medication adherence on reduced violence

Method

Participants (n=1445) were randomly assigned to double-blinded treatment with one of five antipsychotic medications. Analyses are presented for the intention-to-treat sample and for patients completing 6 months on assigned medication

Results

Violence declined from 16% to 9% in the retained sample and from 19% to 14% in the intention-to-treat sample. No difference by medication group was found, except that perphenazine showed greater violence reduction than quetiapine in the retained sample. Medication adherence reduced violence, but not in patients with a history of childhood antisocial conduct. Prospective predictors of violence included childhood conduct problems, substance use, victimisation, economic deprivation and living situation. Negative psychotic symptoms predicted lower violence

Conclusions

Newer antipsychotics did not reduce violence more than perphenazine. Effective antipsychotics are needed, but may not reduce violence unrelated to acute psychopathology

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
      Available formats
      ×

Copyright

Corresponding author

Professor Jeffrey Swanson, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, DUMC Box 3071, Brightleaf Square Suite 23-A, 905 West Main Street, Durham, NC 27710, USA. Email jeffrey.swanson@duke.edu

Footnotes

Hide All

Declaration of interest

J.W.S., M.S.S., R.A.V.D., T.S.S. and H.R.W. have received research support from Eli Lilly, M.S.S. has received consulting and educational fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Pfizer. T.S.S. has received consulting fees from Janssen, GlaxoSmithKline and Bristol-Myers Squibb. J.P.McE. has received research funding from AstraZeneca, Eli Lilly, Janssen and Pfizer, consulting or advisory board fees from Pfizer and Bristol-Myers Squibb, and lecture fees from Janssen and Bristol-Myers Squibb. J.A.L. has received research funding from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen and Pfizer, and consulting and education fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Novartis, Pfizer and Solvay.

Footnotes

References

Hide All
1 Walsh, E, Buchanan, A, Fahy, T. Violence and schizophrenia: examining the evidence. Br J Psychiatry 2002; 180: 490–5.
2 Swanson, JW, Swartz, MS, Elbogen, EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull 2004; 30: 320.
3 Buckley, PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry 1999; 60: 5260.
4 Buckley, PF, Bartell, J, Donenwirth, K, Lee, S, Torigoe, F, Schulz, SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995; 23: 607–11.
5 Citrome, L, Krakowski, M, Greenberg, WM, Andrade, E, Volavka, J. Antiaggressive effect of quetiapine in a patient with schizoaffective disorder. J Clin Psychiatry 2001; 62: 901.
6 Taylor, PJ, Butwell, M, Gray, C, Daly, R, Delal, B, Ferraro, D, Gibb, R, Heads, T, Huckstep, B, Larkin, E, Leese, M, Shetty, G, Winton, M, Tidmarsh, D, Williams, D. Schizophrenia, violence, clozapine and risperidone: a review. Br J Psychiatry 1996; 169: 2130.
7 Volavka, J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry 1999; 60: 43–6.
8 Volavka, J, Czobor, P, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, Cooper, TB, Chakos, M, Lieberman, JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255–62.
9 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
10 Jones, PB, Barnes, TRE, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87.
11 Tiihonen, J, Walhbeck, K, Lonnqvist, J, Klaukka, T, loannidis, JP, Volavka, J, Haukka, J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333: 224–7.
12 Swanson, JW, Van Dorn, RA, Swartz, MS, Smith, A, Elbogen, EB, Monahan, J. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav, in press.
13 Swanson, JW, Swartz, MS, Van Dorn, RA, Elbogen, EB, Wagner, HR, Rosenheck, RA, Stroup, TS, McEvoy, JP, Lieberman, JA. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry 2006; 63: 490–9.
14 Steadman, HJ, Mulvey, EP, Monahan, J, Robbins, PC, Appelbaum, PS, Grisso, T, Roth, LH, Silver, E. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry 1998; 55: 393401.
15 Swanson, JW, Swartz, MS, Elbogen, EB, Van Dorn, RA. Reducing violence risk in persons with schizophrenia: olanzapine vs. risperidone. J Clin Psychiatry 2004; 65: 1666–73.
16 Stroup, TS, McEvoy, JP, Swartz, MS, Byerly, MJ, Glick, ID, Canive, JM, McGee, MF, Simpson, GM, Stevens, MC, Lieberman, JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 1531.
17 Monahan, J, Steadman, H (eds). Violence and Mental Disorder: Developments in Risk Assessment. University of Chicago Press, 1994.
18 Link, BG, Stueve, A, Phelan, J. Psychotic symptoms and violent behaviors: probing the components of ‘threat/control override’ symptoms. Soc Psychiatry Psychiatr Epidemiol 1998; 33: s5560.
19 Swanson, J, Estroff, S, Swartz, M, Borum, R, Lachicotte, W, Zimmer, C, Wagner, R. Violence and severe mental disorder in clinical and community populations: the effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry 1997; 60: 122.
20 Farrington, DP, Loeber, R. Some benefits of dichotomization in psychiatric and criminological research. Crim Behav Ment Health 2000; 10: 100–22.
21 George, L, Blazer, D, Hughes, D, Fowler, N. Social support and the outcomes of major depression. Br J Psychiatry 1989; 186: 651–6.
22 First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for Axes I and II DSM–IV Disorders – Patient Edition (SCID–I/P). Biometrics Research Department, New York State Psychiatric Institute, 1996.
23 Guy, W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual. National Institute of Menta Health, 1976.
24 Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.
25 Addington, D, Addington, J, Schissel, B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247–51.
26 McEvoy, JP, Aland, JJ, Wilson, WH, Guy, W, Hawkins, L. Measuring chronic schizophrenic patients attitudes toward their illness and treatment. Hosp Community Psychiatry 1981; 32: 856–8.
27 Swartz, MS, Wagner, HR, Swanson, JW, Stroup, TS, McEvoy, JP, Canive, JM, Miller, DD, Reimherr, F, McGee, M, Khan, A, Van Dorn, R, Rosenheck, RA, Lieberman, JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006; 194: 164–72.
28 Heinrichs, DW, Hanlon, ET, Carpenter, WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–98.
29 Fleiss, JL, Williams, JB, Dubro, AF. The logistic regression analysis of psychiatric data. J Psychiatr Res 1986; 20: 145209.
30 Hosmer, D, Lemeshow, S. Applied Logistic Regression (2nd edn). Wiley, 2000.
31 Snijders, TAB, Bosker, RJ. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. Sage, 1999.
32 Swanson, JW. Mental disorder, substance abuse, and community violence: an epidemiological approach. In Violence and Mental Disorder: Developments in Risk Assessment (eds Monahan, J, Steadman, H): 101–36. University of Chicago Press, 1994.
33 Wallace, C, Mullen, PE, Burgess, P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry 2004; 161: 716–27.
34 Hiday, VA, Swanson, JW, Swartz, MS, Borum, R, Wagner, HR. Victimization: a link between mental illness and violence? Int J Law Psychiatry 2001; 24: 559–72.
35 Link, BG, Stueve, A. Psychotic symptoms and the violent/illegal behavior of mental patients compared to community controls. In Violence and Mental Disorder: Developments in Risk Assessment (eds Monahan, J, Steadman, H): 137160. University of Chicago Press, 1994.
36 Mullen, PE. Schizophrenia and violence: from correlations to preventive strategies. Advan Psychiatr Treat 2006; 12: 239–48.
37 Swanson, JW, Borum, R, Swartz, MS, Monahan, J. Psychotic symptoms and disorders and the risk of violent behavior in the community. Crim Behav Ment Health 1996; 6: 317–38.
38 Swanson, JW, Swartz, MS, Essock, SM, Osher, FC, Wagner, HR, Goodman, LA, Rosenberg, SD, Meador, KG. The social-environmental context of violent behavior in persons treated for severe mental illness. Am J Publ Health 2002; 92: 1523–31.
39 Appelbaum, PS, Robbins, PC, Monahan, J. Violence and delusions: data from the MacArthur Violence Risk Assessment Study. Am J Psychiatry 2000; 157: 566–72.
40 Herrera, JN, Sramek, JJ, Costa, JF, Roy, S, Heh, CW, Nguyen, BN. High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis 1988; 176: 558–61.
41 Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006; 63: 622–9.
42 Volavka, J, Czobor, P, Nolan, K, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, Cooper, TB, Lieberman, JA. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004; 24: 225–8.
43 Nolan, KA, Volavka, J, Mohr, P, Czobor, P. Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr Serv 1999; 50: 787–92.
Type Description Title
PDF
Supplementary materials

Swanson et al. supplementary material
Supplementary Table S1

 PDF (37 KB)
37 KB
UNKNOWN
Supplementary materials

Swanson et al. supplementary material
Supplementary Material

 Unknown (473 bytes)
473 bytes

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

  • Jeffrey W. Swanson (a1), Marvin S. Swartz (a1), Richard A. Van Dorn (a2), Jan Volavka (a3), John Monahan (a4), T. Scott Stroup (a5), Joseph P. McEvoy (a1), H. Ryan Wagner (a1), Eric B. Elbogen (a1) and Jeffrey A. Lieberman (a6)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *